GENE - CHEMICAL INTERACTIONS REPORT
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction
is comprised of a complex set of reactions and/or regulatory events, possibly involving
additional chemicals and/or gene products.
Object Symbol | Qualifier | Evidence | With | Reference | Source | Notes | Original Reference(s) | NLRP3 | multiple interactions | EXP | | 6480464 | CTD | [Uric Acid co-treated with Lipopolysaccharides] results in increased activity of NLRP3 protein; NLRP3 protein affects the reaction [Uric Acid results in increased cleavage of CASP1 protein]; NLRP3 protein affects the reaction [Uric Acid results in increased secretion of IL1B protein] | PMID:18403674 PMID:18604214 | NLRP3 | decreases response to substance | ISO | Nlrp3 (Mus musculus) | 6480464 | CTD | NLRP3 gene mutant form results in decreased susceptibility to Uric Acid | PMID:23619996 | NLRP3 | multiple interactions | ISO | Nlrp3 (Mus musculus) | 6480464 | CTD | [Lipopolysaccharides co-treated with Uric Acid] affects the localization of NLRP3 protein; [Lipopolysaccharides co-treated with Uric Acid] promotes the reaction [PYCARD protein binds to CASP1 protein binds to IL1B protein binds to NLRP3 protein]; diallyl trisulfide inhibits the reaction [[Lipopolysaccharides co-treated with Uric Acid] affects the localization of NLRP3 protein]; diallyl trisulfide inhibits the reaction [[Lipopolysaccharides co-treated with Uric Acid] promotes the reaction [PYCARD protein binds to CASP1 protein binds to IL1B protein binds to NLRP3 protein]]; NLRP3 gene mutant form inhibits the reaction [Uric Acid results in decreased expression of BRCA1 mRNA]; NLRP3 gene mutant form inhibits the reaction [Uric Acid results in decreased expression of CCNB1 mRNA]; NLRP3 gene mutant form inhibits the reaction [Uric Acid results in decreased expression of CCND1 mRNA]; NLRP3 gene mutant form inhibits the reaction [Uric Acid results in decreased expression of OGG1 mRNA]; NLRP3 gene mutant form inhibits the reaction [Uric Acid results in decreased expression of POLB mRNA]; NLRP3 gene mutant form inhibits the reaction [Uric Acid results in decreased expression of PRIM1 mRNA]; NLRP3 gene mutant form inhibits the reaction [Uric Acid results in decreased expression of RAD51 mRNA]; NLRP3 gene mutant form inhibits the reaction [Uric Acid results in decreased expression of RFC3 mRNA]; NLRP3 gene mutant form inhibits the reaction [Uric Acid results in decreased expression of RFC4 mRNA]; NLRP3 gene mutant form inhibits the reaction [Uric Acid results in decreased expression of TTK mRNA]; NLRP3 gene mutant form inhibits the reaction [Uric Acid results in decreased expression of TYMS mRNA]; NLRP3 gene mutant form inhibits the reaction [Uric Acid results in decreased expression of XRCC1 mRNA]; NLRP3 gene mutant form inhibits the reaction [Uric Acid results in increased phosphorylation of ATR protein]; NLRP3 gene mutant form inhibits the reaction [Uric Acid results in increased phosphorylation of H2AX protein]; NLRP3 protein affects the reaction [[Lipopolysaccharides co-treated with Uric Acid] results in increased cleavage of CASP1 protein]; NLRP3 protein affects the reaction [[Lipopolysaccharides co-treated with Uric Acid] results in increased secretion of and results in increased cleavage of IL1B protein]; NLRP3 protein affects the reaction [Uric Acid results in increased cleavage of CASP1 protein]; NLRP3 protein affects the reaction [Uric Acid results in increased secretion of IL1B protein] | PMID:18403674 PMID:18604214 PMID:23619996 PMID:36796188 | | ||||||||||||||||||||||
| Go Back to source page | Continue to Ontology report |